ArticleFrontiers in oncology2026
BrainFusionNet: an attention-augmented deep convolutional framework with hybrid loss optimisation and test-time augmentation for multi-class brain tumour detection in magnetic resonance images.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accurate and timely identification of brain tumours from Magnetic Resonance Imaging (MRI) scans remains one of the most clinically consequential problems in medical image analysis, because the four principal tumour categories - glioma, meningioma, pituitary adenoma, and the tumour-free condition - share overlapping intensity profiles and highly variable morphological presentations. This research introduces BrainFusionNet, a novel deep learning pipeline built on an ImageNet-pre-trained EfficientNet-B4 backbone augmented with a Convolutional Block Attention Module (CBAM) and trained with a hybrid loss combining label-smoothing cross-entropy and focal loss. A structured two-phase fine-tuning strategy - frozen early layers during warm-up, followed by full-network unfreezing under a Cosine Annealing with Warm Restarts (CAWR) schedule - maximises generalisation from a moderately sized dataset. At inference time, a five-fold Test-Time Augmentation (TTA) ensemble further sharpens predictions. Evaluated on the publicly available Kaggle Brain Tumour MRI dataset comprising 7-200 annotated scans across four classes, BrainFusionNet achieves a test accuracy of 99.81%, a macro-averaged F1-score of 99.78%, and a mean AUC of 0.9994 - surpassing every compared baseline, including ResNet-50, DenseNet-201, EfficientNet-B4 (standalone), and ViT-B/16, with statistical superiority confirmed by McNemar tests (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.